Literature DB >> 25474475

Comparison of hospital mortality and long-term survival in patients with acute lung injury/ARDS vs cardiogenic pulmonary edema.

Christopher N Schmickl1, Michelle Biehl2, Gregory A Wilson3, Ognjen Gajic3.   

Abstract

BACKGROUND: Early differential diagnosis of acute lung injury (ALI) vs cardiogenic pulmonary edema (CPE) is important for selecting the most appropriate therapy, but the prognostic implications of this distinction have not been studied. Accurate prognostic information is essential for providing appropriate informed consent prior to initiation of mechanical ventilation.
METHODS: This is a long-term follow-up study of a previously established population-based cohort of critically ill adult patients with acute pulmonary edema admitted at a tertiary-care center during 2006 to 2009, in which post hoc expert review had established ALI vs CPE diagnosis. Using logistic and Cox regression, hospital mortality and long-term survival were compared in patients with ALI vs patients with CPE.
RESULTS: Of 328 patients (ALI = 155, CPE = 173), 240 patients (73%) died during a median follow-up of 160 days. After adjusting for confounders, patients with ALI were significantly more likely to die in the hospital (OR = 4.2, 95% CI = 2.3-7.8, n = 325, P < .001), but among hospital survivors the risk of death during follow-up was the same in both groups (hazard ratio = 1.13, 95% CI = 0.79-1.62, n = 229, P = .50). Independent predictors of mortality included age and APACHE (Acute Physiology and Chronic Health Evaluation) III score. Results were similar when restricting patients with ALI to the subset with ARDS (Berlin definition). In post hoc analyses, the mortality rate in hospital survivors compared with the general US population was significantly higher during the first 2 years but essentially converged by year five.
CONCLUSIONS: Although hospital mortality is higher in patients with ALI/ARDS compared with patients with CPE, long-term survival is similar in hospital survivors from both groups.

Entities:  

Mesh:

Year:  2015        PMID: 25474475     DOI: 10.1378/chest.14-1371

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Fraxinol attenuates LPS-induced acute lung injury by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas and inhibiting NLRP3.

Authors:  Yan Wu; Xin Yang; Yuanyuan Ju; Fei Zhao
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

2.  Clinical Predictors of Hospital Mortality Differ Between Direct and Indirect ARDS.

Authors:  Liang Luo; Ciara M Shaver; Zhiguo Zhao; Tatsuki Koyama; Carolyn S Calfee; Julie A Bastarache; Lorraine B Ware
Journal:  Chest       Date:  2016-09-20       Impact factor: 9.410

3.  Prognostic factors in the acute respiratory distress syndrome.

Authors:  Wei Chen; Lorraine B Ware
Journal:  Clin Transl Med       Date:  2015-07-02

4.  Xenogeneic human umbilical cord-derived mesenchymal stem cells reduce mortality in rats with acute respiratory distress syndrome complicated by sepsis.

Authors:  Fan-Yen Lee; Kuan-Hung Chen; Christopher Glenn Wallace; Pei-Hsun Sung; Jiunn-Jye Sheu; Sheng-Ying Chung; Yung-Lung Chen; Hung-I Lu; Sheung-Fat Ko; Cheuk-Kwan Sun; Hsin-Ju Chiang; Hsueh-Wen Chang; Mel S Lee; Hon-Kan Yip
Journal:  Oncotarget       Date:  2017-07-11

5.  Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury.

Authors:  Gan Zhao; Tao Zhang; Xiaofei Ma; Kangfeng Jiang; Haichong Wu; Changwei Qiu; Mengyao Guo; Ganzhen Deng
Journal:  Oncotarget       Date:  2017-07-12

6.  Xenogeneic and Allogeneic Mesenchymal Stem Cells Effectively Protect the Lung Against Ischemia-reperfusion Injury Through Downregulating the Inflammatory, Oxidative Stress, and Autophagic Signaling Pathways in Rat.

Authors:  Kun-Chen Lin; Jun-Ning Yeh; Yi-Ling Chen; John Y Chiang; Pei-Hsun Sung; Fan-Yen Lee; Jun Guo; Hon-Kan Yip
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.